PYC
Fiscal year ends June Quarters are offset from the calendar — Q1 is Jul–Sep

PYC Therapeutics is a clinical-stage biotechnology company developing RNA therapies for rare monogenic diseases. The company utilizes a proprietary drug delivery platform based on cell-penetrating peptides to enhance the intracellular potency of RNA therapeutics, targeting the underlying genetic causes of conditions with limited or no available treatments. Its pipeline includes four drug candidates: PYC-003 for Polycystic Kidney Disease, PYC-001 for Autosomal Dominant Optic Atrophy, VP-001 for Retinitis Pigmentosa type 11, and PYC-002 for Phelan-McDermid Syndrome. Three of these candidates are currently in clinical development, while the fourth is in pre-clinical stages. The company holds a majority shareholding in Vision Pharma Pty Ltd, the entity that owns VP-001. PYC Therapeutics focuses on disease areas including the kidney, central nervous system, and retina, with operational activities in Australia and the United States.

Summarised from the company's own disclosures, fiscal year ended Jun 2026

Industry Pharmaceuticals, Biotechnology & Life Sciences Homepage pyctx.com
Sector Healthcare IR page pyctx.com/investors
Tags
rna therapeutics, monogenic diseases, drug delivery, cell-penetrating peptides, rare diseases, ophthalmology, nephrology, neurology, clinical-stage, gene expression, PYC-003, PYC-001, VP-001, PYC-002, Vision Pharma Pty Ltd
Press page —

Metrics

Valuation  
Market cap A$ 1.901B
Market cap (USD) $ 1.306B
P/E -43.09
PEG —
P/BV 2.70
P/S 47.90
P/OCF -42.69
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE -10.1%
ROI -6.3%
ROIC -6.3%
Profit margin -110.3%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -17.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Revenue 39.677M 26.171M 22.855M 15.908M 16.067M 3.242M 2.665M 0 0 — — — — — — — —
Net profit -43.768M -51.013M -38.11M -23.356M -14.294M -18.63M -7.08M -4.08M -7.434M -1.951M -3.979M -2.991M -3.258M -3.44M -3.905M -3.605M -4.573M

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Share price 1.21 — — — — — — — — — — — — — — — —
P/OCF -26.73 — — — — — — — — — — — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

PKD Program - Enrolment Target Met Bull 3 Bear 0 Clinical/regulatory
Results of Annual General Meeting Bull 0 Bear 0 Routine

Prompts

PYC Therapeutics Limited (ticker PYC), listed in Australia.

ETFs Holding PYC Therapeutics Limited

ETF Weight in ETF Shares Market value As of
AVDS 0.04% 124,900 $ 149.69K Nov 16, 2026